Alazocin

Alazocin
IUPAC ime
	(2R,6R,11R)- 6,11-dimethyl- 3-prop- 2-en- 1-yl- 1,2,3,4,5,6-hexahydro- 2,6-methano- 3-benzazocin- 8-ol 2-allyl- 5,9-dimethyl- 2'-hydroxy- 6,7-benzomorphan
Klinički podaci
Način primene	?
Pravni status
Pravni status	Uncontrolled;
Identifikatori
CAS broj	14198-28-8
ATC kod	none
PubChem	CID 3036246
ChemSpider	2300306
Hemijski podaci
Formula	C17H23NO
Molarna masa	257.37 g/mol
	SMILES C[C@H]1[C@H]2CC3=C([C@@]1(CCN2CC=C)C)C=C(C=C3)O; ;

Alazocin ((-)-SKF-10,047, (-)-N-alilnormetazocin, (-)-ANMC), je bio prvi lek koji je agonist σ₁ receptora (K_i = 24 nM).^[1]^[2]^[3] On nema značajan afinitet za σ₂ receptor.^[3] Alazocin takođe deluje kao agonist κ-opioidnog receptora (K_i = 0.4 nM), i u znatno manjoj meri kao antagonist NMDA receptora (K_i = 587 nM).^[3]^[4]

^ Iwamoto, ET (1981). „Pharmacologic effects of N-allylnormetazocine (SKF-10047)”. NIDA research monograph. 34: 82—8. PMID 6783955.
^ Shearman, GT; Herz, A (1982). „Non-opioid psychotomimetic-like discriminative stimulus properties of N-allylnormetazocine (SKF 10,047) in the rat”. European journal of pharmacology. 82 (3-4): 167—72. PMID 6290235.
^ ^а ^б ^в Chou YC, Liao JF, Chang WY, Lin MF, Chen CF (1999). „Binding of dimemorfan to sigma-1 receptor and its anticonvulsant and locomotor effects in mice, compared with dextromethorphan and dextrorphan”. Brain Research. 821 (2): 516—9. PMID 10064839. doi:10.1016/S0006-8993(99)01125-7.
^ Gharagozlou P, Hashemi E, DeLorey TM, Clark JD, Lameh J (2006). „Pharmacological profiles of opioid ligands at kappa opioid receptors”. BMC Pharmacology. 6: 3. PMC 1403760 . PMID 16433932. doi:10.1186/1471-2210-6-3.